(PharmaNewsWire.Com, December 16, 2017 ) Multiple Myeloma is an affliction of kidney which also affects bone and blood cells. Loss of appetite, severe fatigue, increased urination and pain in the bones are its most common symptoms. A combination of urine tests, bone marrow tests, and several blood tests are required to ascertain the presence of this disease. Men are more likely to contract Multiple Myeloma market as compared to women and the chances increase as one grows older.
Multiple Myeloma Therapeutics Market: Drivers & Restraints Factors such as augmenting geriatric population in the European countries coupled with rising number of cases of chronic diseases are some of the main hinderances to the market growth in this region.
Several cases of patient health deterioration after treatment and ripen treatment resistance have been reported which is the primary restraint of this market.
By Treatment Type • Chemotherapy o Anthracycline Antibiotic o Alkylating agent • Targeted Therapy o Proteasome inhibitor
By Drug Type • Corticosteroids o Dexamethasone (Decadron) o Prednisone (Deltasone/Orasone) • Immunomodulatory agents o Thalidomide (Thalomid) o Lenalidomide (Revlimid) o Arsenic trioxide (Trisenox) o Plerixafor (Mozobil)
By Geography • Europe o U.K o Spain o Germany o Italy o France
From simple data collation through secondary and primary research to ad-hoc research requests relating to specific information, we provide our services via customization.
In 2017, by treatment type Chemotherapy was the market leader and is predicted to maintain its lead in the aforementioned forecast period. Lack of alternatives and limited surgical procedures are the factors attributable to the observable trend mentioned above. If we go by drug type than Immunomodulation agent lead the market. However, monoclonal antibodies segment is predicted to grow with the highest CAGR in the aforementioned forecast period.
As 0f 2017, Europe accounted for the second largest share of the Multiple Myeloma Therapeutics Market in the aforementioned forecast period. Presence of a lot of companies, easy adoption of newer treatment options are the factors attributable to the observable trend mentioned above.
Multiple Myeloma Therapeutics Market: Key Players Some of the major companies competing in the Multiple Myeloma Therapeutics are MAB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC., ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc., Teva Pharmaceutical Industries Ltd., TG Therapeutics Inc. and Johnson and Johnson.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
